- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03527459
Implementing an IPTS Treatment Approach to Improve Outcomes in Suicidal Youth
October 30, 2019 updated by: Sunita Stewart, University of Texas Southwestern Medical Center
Implementing an Interpersonal Theory of Suicide Treatment Approach to Improve Outcomes in Suicidal Youth
The purpose of this project is to evaluate a set of interventions derived from a theory of suicide that supplements a clinical program and compare their effects on outcomes to the outcomes of the unsupplemented program.
This study proposes to evaluate the effect of these interventions on reducing specific negative cognitions associated with depression and suicide ideation in an intensive outpatient program for suicidal youth (Suicide Prevention and Resilience at Children's, SPARC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The trial will be conducted in a program where half of the clients are enrolled into either the original program (SPARC A which has a general focus on negative cognitions) or SPARC B (which will overlap significantly with SPARC A but targets in some sessions specific negative cognitions of perceived burdensomeness).
The program is already structured so that each patient consistently attends either a morning or an afternoon track, with different therapists running each track.
This allows for separate programs in each track.
Clinically justifiable innovations are routinely introduced into the program usually in a stepwise fashion in one or another part by one set of therapists at a time.
The investigators propose to take advantage of this partial introduction by assessing relative impact of SPARC A and SPARC B on depressive symptoms and suicide ideation.
The investigators have no data to indicate that one program will be better than the other.
The investigation will, however, allow the investigators to assess whether this innovation in fact is effective.
Patients will not be randomized at the individual level, but rather their time slot (usually decided based on opening within the program) will place them into either SPARC A or SPARC B. The two programs are of identical length with numerous features in common, differing only in the specificity of the exercises and examples and their relevance to perceived burdensomeness.
Routine assessments at entry and discharge from the program will not change based on study enrollment.
However, suicide ideation, depressive symptoms, and negative cognitions (perceived burdensomeness and thwarted belongingness) will be more formally assessed at the one-month follow-up meeting or phone call which will add approximately 10 minutes to the contact.
Study Type
Interventional
Enrollment (Actual)
123
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75235
- Children's Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adolescents, ages 12 - 17
- enrolled in the SPARC program at Children's Medical Center of Dallas
- completed at least 5 SPARC group therapy sessions
Exclusion Criteria:
- adolescents who have previously received treatment in the control arm of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: SPARC A
SPARC A is an existing clinical program which has a general focus on negative cognitions.
|
SPARC A is an existing clinical program with a general focus on negative cognitions.
|
|
Experimental: SPARC B
SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
|
SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interpersonal Needs Questionnaire (INQ) (Van Orden et al., 2012)
Time Frame: through program completion, an average of 6 weeks
|
change in perceived burdensomeness
|
through program completion, an average of 6 weeks
|
|
Concise Health Risk Tracking Self Report (CHRT-SR) (Trivedi et al., 2011)
Time Frame: through program completion, an average of 6 weeks
|
suicide ideation (self-report)
|
through program completion, an average of 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quick Inventory of Depressive Symptomatology - Adolescent Version Self-Report (QIDS-A-SR-16) (Bernstein et al., 2010)
Time Frame: through program completion, an average of 6 weeks
|
change in depressive symptoms
|
through program completion, an average of 6 weeks
|
|
Interpersonal Needs Questionnaire (INQ) (Van Orden et al., 2012)
Time Frame: 1 month after program completion
|
change in perceived burdensomeness
|
1 month after program completion
|
|
Concise Health Risk Tracking Self Report (CHRT-SR) (Trivedi et al., 2011)
Time Frame: 1 month after program completion
|
change in suicide ideation (self-report)
|
1 month after program completion
|
|
Quick Inventory of Depressive Symptomatology - Adolescent Version Self-Report (QIDS-A-SR-16) (Bernstein et al., 2010)
Time Frame: 1 month after program completion
|
change in depressive symptoms
|
1 month after program completion
|
|
Concise Health Risk Tracking Self Report (CHRT-SR)
Time Frame: between program completion, an average of 6 weeks, and 1 month after program completion
|
change in suicide ideation (self-report)
|
between program completion, an average of 6 weeks, and 1 month after program completion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sunita M. Stewart, PhD, UT Southwestern Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Van Orden KA, Cukrowicz KC, Witte TK, Joiner TE. Thwarted belongingness and perceived burdensomeness: construct validity and psychometric properties of the Interpersonal Needs Questionnaire. Psychol Assess. 2012 Mar;24(1):197-215. doi: 10.1037/a0025358. Epub 2011 Sep 19.
- Bernstein IH, Rush AJ, Trivedi MH, Hughes CW, Macleod L, Witte BP, Jain S, Mayes TL, Emslie GJ. Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. Int J Methods Psychiatr Res. 2010 Dec;19(4):185-94. doi: 10.1002/mpr.321.
- Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, Nierenberg AA, Gaynes BN, Husain MM, Luther JF, Zisook S, Rush AJ. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011 Jun;72(6):757-64. doi: 10.4088/JCP.11m06837.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 14, 2017
Primary Completion (Actual)
March 7, 2019
Study Completion (Actual)
June 1, 2019
Study Registration Dates
First Submitted
May 2, 2018
First Submitted That Met QC Criteria
May 15, 2018
First Posted (Actual)
May 17, 2018
Study Record Updates
Last Update Posted (Actual)
November 1, 2019
Last Update Submitted That Met QC Criteria
October 30, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GA2016-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
Clinical Trials on SPARC A
-
Sun Pharma Advanced Research Company LimitedCompletedSpasticityUnited States, Russian Federation, Ukraine
-
Sun Pharma Advanced Research Company LimitedCompleted
-
Sun Pharma Advanced Research Company LimitedCompletedBreast Cancer and Ovarian Cancer
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedCorneal Infiltrative Events | Corneal InflammationUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
CooperVision International Limited (CVIL)Completed
-
CooperVision, Inc.Completed